JPWO2020072824A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020072824A5 JPWO2020072824A5 JP2021518472A JP2021518472A JPWO2020072824A5 JP WO2020072824 A5 JPWO2020072824 A5 JP WO2020072824A5 JP 2021518472 A JP2021518472 A JP 2021518472A JP 2021518472 A JP2021518472 A JP 2021518472A JP WO2020072824 A5 JPWO2020072824 A5 JP WO2020072824A5
- Authority
- JP
- Japan
- Prior art keywords
- scleroderma
- systemic sclerosis
- compound
- hydrate
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010039710 Scleroderma Diseases 0.000 claims 28
- 206010042953 Systemic sclerosis Diseases 0.000 claims 26
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 22
- 229940125904 compound 1 Drugs 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 19
- 239000012453 solvate Substances 0.000 claims 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 18
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 15
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims 14
- 206010001889 Alveolitis Diseases 0.000 claims 9
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 9
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 9
- 201000003088 Limited Scleroderma Diseases 0.000 claims 8
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 6
- 201000002829 CREST Syndrome Diseases 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 4
- 208000024140 Limited cutaneous systemic sclerosis Diseases 0.000 claims 4
- 208000000185 Localized scleroderma Diseases 0.000 claims 4
- 206010027982 Morphoea Diseases 0.000 claims 4
- 230000004761 fibrosis Effects 0.000 claims 4
- -1 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl Chemical group 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 3
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000024134 Diffuse cutaneous systemic sclerosis Diseases 0.000 claims 2
- 206010042954 Systemic sclerosis pulmonary Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000016809 linear scleroderma Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- MVGWUTBTXDYMND-QGZVFWFLSA-N 2-[(3r)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid Chemical compound C([C@@H]1CC(=O)O)CC(C2=C3)=C1NC2=CC=C3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 MVGWUTBTXDYMND-QGZVFWFLSA-N 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010060708 Induration Diseases 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010040882 skin lesion Diseases 0.000 claims 1
- 231100000444 skin lesion Toxicity 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023055658A JP2023082117A (ja) | 2018-10-03 | 2023-03-30 | 強皮症の治療のための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862740855P | 2018-10-03 | 2018-10-03 | |
| US62/740,855 | 2018-10-03 | ||
| PCT/US2019/054576 WO2020072824A1 (en) | 2018-10-03 | 2019-10-03 | Methods for the treatment of scleroderma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023055658A Division JP2023082117A (ja) | 2018-10-03 | 2023-03-30 | 強皮症の治療のための方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022504181A JP2022504181A (ja) | 2022-01-13 |
| JPWO2020072824A5 true JPWO2020072824A5 (https=) | 2022-09-29 |
| JP2022504181A5 JP2022504181A5 (https=) | 2022-09-29 |
| JP7265620B2 JP7265620B2 (ja) | 2023-04-26 |
Family
ID=68290393
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518472A Active JP7265620B2 (ja) | 2018-10-03 | 2019-10-03 | 強皮症の治療のための方法 |
| JP2023055658A Pending JP2023082117A (ja) | 2018-10-03 | 2023-03-30 | 強皮症の治療のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023055658A Pending JP2023082117A (ja) | 2018-10-03 | 2023-03-30 | 強皮症の治療のための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210386706A1 (https=) |
| EP (1) | EP3860590B1 (https=) |
| JP (2) | JP7265620B2 (https=) |
| ES (1) | ES2951870T3 (https=) |
| WO (1) | WO2020072824A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201906876PA (en) | 2010-01-27 | 2019-09-27 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| MX386419B (es) | 2015-01-06 | 2025-03-18 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
| EP3939965A1 (en) | 2015-06-22 | 2022-01-19 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| WO2018151834A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| ES2987794T3 (es) | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001003739A1 (fr) * | 1999-07-12 | 2001-01-18 | Ono Pharmaceutical Co., Ltd. | Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate |
| EA019252B1 (ru) * | 2008-07-23 | 2014-02-28 | Арена Фармасьютикалз, Инк. | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ (1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ |
| SG10201906876PA (en) | 2010-01-27 | 2019-09-27 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| MX386419B (es) | 2015-01-06 | 2025-03-18 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
| EP3939965A1 (en) * | 2015-06-22 | 2022-01-19 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders |
| MA47504A (fr) * | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| WO2018151834A1 (en) * | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| ES2987794T3 (es) * | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
| US20220142977A1 (en) * | 2019-01-08 | 2022-05-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
-
2019
- 2019-10-03 US US17/281,748 patent/US20210386706A1/en not_active Abandoned
- 2019-10-03 JP JP2021518472A patent/JP7265620B2/ja active Active
- 2019-10-03 EP EP19790404.8A patent/EP3860590B1/en not_active Revoked
- 2019-10-03 ES ES19790404T patent/ES2951870T3/es active Active
- 2019-10-03 WO PCT/US2019/054576 patent/WO2020072824A1/en not_active Ceased
-
2023
- 2023-03-30 JP JP2023055658A patent/JP2023082117A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022504181A5 (https=) | ||
| JP2023076465A5 (https=) | ||
| JP3667381B2 (ja) | 解熱鎮痛剤 | |
| CN103429236B (zh) | 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物 | |
| US20230414519A1 (en) | Rapidly infusing compositions with methotrexate and treatment methods | |
| HU225887B1 (en) | Process for producing pharmaceutical compositions containing flurbiprofen having painkiller activity | |
| JP2011522816A5 (https=) | ||
| JP2021073257A5 (https=) | ||
| JP2007533687A5 (https=) | ||
| Nordbladh et al. | Analgesia in tonsillectomy: a double‐blind study on pre and post‐operative treatment with diclofenac | |
| JPWO2020072824A5 (https=) | ||
| JP2011520980A5 (https=) | ||
| JP2002544227A5 (https=) | ||
| JPH05148139A (ja) | イブプロフエン含有解熱鎮痛剤 | |
| JP2020533402A5 (https=) | ||
| JP2013518061A5 (https=) | ||
| CN109310669B (zh) | 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途 | |
| JP2008534563A5 (https=) | ||
| ES2358564T3 (es) | Derivados de carbonilamino útiles para el tratamiento de una enfermedad inflamatoria intestinal. | |
| JPWO2020112880A5 (https=) | ||
| WO2016121147A1 (ja) | 注腸剤 | |
| JP2015520759A5 (https=) | ||
| CN105079012B (zh) | 天麻素在制备防治溃疡性结肠炎的药物或食品中的应用 | |
| ES2360461T3 (es) | Agente preventivo o terapéutico para enfermedad inflamatoria del intestino. | |
| JPWO2021142030A5 (https=) |